Johnson & Johnson to acquire Ollin Biosciences
Editor’s note: This is a developing news story. Please check back soon for updates.
Johnson & Johnson has a definitive agreement to acquire Ollin Biosciences, according to a press release.
Johnson & Johnson will pay $2.2 billion upfront, with an additional $1.125 billion in potential payments tied to regulatory and commercial milestones, according to the release. The deal is expected to close before the end of the year.
The company will add OLN324, Ollin’s phase 3 investigational bispecific antibody, to its pipeline. The therapy targets both VEGF and angiopoietin-2 and is in development